GSK
3 years ago ⋅ English ⋅ 5 min read
Newsroom
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040

For media and investors onlyReport from Economist Impact offers key actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, mental healt... Read More
GSK
3 years ago ⋅ English ⋅ 8 min read
Newsroom
GSK to showcase significant scientific advances in renal care at the American Society of Nephrology Kidney Week 2021

For media and investors only- Late-breaking Phase 3 data will provide new evidence for daprodustat as a potential treatment for patients with anaemia due to chronic kidney disease in bo... Read More
GSK
3 years ago ⋅ English ⋅ 2 min read
Newsroom
GSK unveils plan for UK headquarters of new Consumer Healthcare company

For media and investors only- New UK-listed Consumer Healthcare company to build new global campus and innovation centre in Weybridge, UK- GSK unveils longer-term plan to move to new UK... Read More
GSK
3 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine

For media and investors onlyIssued: 6 October, London UK- Based on the recommendation of its global advisory bodies for immunization and malaria, WHO has recommended the wider use of GS... Read More
GSK
3 years ago ⋅ English ⋅ 7 min read
Newsroom
ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV

For media and investors onlyIssued: 4 October, London UKViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders,... Read More
GSK
3 years ago ⋅ English ⋅ 8 min read
Newsroom
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

For media and investors onlyIssued: 29 September 2021, London UKThe Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable sw... Read More